<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3004257315
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ENEVOM 80 MG CAPSULE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        APREPITANT
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        80
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        79.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Rontis Hellas S.A., Medical and Pharmaceutical Products" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Rontis Hellas S.A., Medical and Pharmaceutical Products
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MS Pharma Saudi (MSPS)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Enevom</strong> contains the active substance aprepitant and belongs to a group of medicines called &ldquo;neurokinin 1 (NK1) receptor antagonists&rdquo;. The brain has a specific area that controls nausea and vomiting. <strong>Enevom</strong>works by blocking signals to that area, thereby reducing nausea and vomiting. <strong>Enevom</strong> capsules are used in adults and adolescents from the age of 12 years in combination with other medicines to prevent nausea and vomiting caused by chemotherapy (cancer treatment) that are strong and moderate triggers of nausea and vomiting (such as cisplatin, cyclophosphamide, doxorubicin or epirubicin).</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p dir="LTR"><strong>2.Before you take Enevom</strong></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Enevom:</strong></p><p>&bull;if you or the child is allergic to aprepitant or any of the other ingredients of this medicine (listed in section 6).</p><p>&bull;with medicines containing pimozide (used to treat psychiatric illnesses), terfenadine and astemizole (used for hay fever and other allergic conditions), cisapride (used for treating digestive problems). Tell the doctor if you or the child is taking these medicines since the treatment must be modified before you or the child start taking <strong>Enevom</strong>.</p><p><strong>Warnings and precautions</strong></p><p>Talk to the doctor, pharmacist, or nurse before you take <strong>Enevom</strong> or give this medicine to the child.</p><p>Before treatment with <strong>Enevom</strong>, tell the doctor if you or the child have liver disease because the liver is important in breaking down the medicine in the body. The doctor may therefore have to monitor the condition of your or the child&rsquo;s liver.</p><p><strong>Children and adolescents</strong></p><p>Do not give <strong>Enevom</strong> 80 mg and 125 mg capsules to children under 12 years of age, because the 80 mg and 125 mg capsules have not been studied in this population.</p><p><strong>Other medicines and Enevom</strong></p><p><strong>Enevom</strong> can affect other medicines both during and after treatment with <strong>Enevom</strong>. There are some medicines that should not be taken with <strong>Enevom</strong> (such as pimozide, terfenadine, astemizole, and cisapride) or that require a dose adjustment (see also &lsquo;Do not take <strong>Enevom</strong>&rsquo;).</p><p>The effects of <strong>Enevom</strong> or other medicines might be influenced if you or the child take <strong>Enevom</strong> together with other medicines including those listed below. Please talk to the doctor or pharmacist if you or the child is taking any of the following medicines:</p><p>&bull;birth control medicines which can include birth control pills, skin patches, implants, and certain Intrauterine devices (IUDs) that release hormones may not work adequately when taken together with <strong>Enevom</strong>. Another or additional non-hormonal form of birth control should be used during treatment with <strong>Enevom</strong> and for up to 2 months after using <strong>Enevom</strong>,</p><p>&bull;cyclosporine, tacrolimus, sirolimus, everolimus (immunosuppressants),</p><p>&bull;alfentanil, fentanyl (used to treat pain),</p><p>&bull;quinidine (used to treat an irregular heart beat),</p><p>&bull;irinotecan, etoposide, vinorelbine, ifosfamide (medicines used to treat cancer),</p><p>&bull;medicines containing ergot alkaloid derivatives such as ergotamine and diergotamine (used for treating migraines),</p><p>&bull;warfarin, acenocoumarol (blood thinners; blood tests may be required),</p><p>&bull;rifampicin, clarithromycin, telithromycin (antibiotics used to treat infections),</p><p>&bull;phenytoin (a medicine used to treat seizures),</p><p>&bull;carbamazepine (used to treat depression and epilepsy),</p><p>&bull;midazolam, triazolam, phenobarbital (medicines used to produce calmness or help you sleep),</p><p>&bull;St. John&rsquo;s Wort (an herbal preparation used to treat depression),</p><p>&bull;protease inhibitors (used to treat HIV infections)</p><p>&bull;ketoconazole except shampoo (used to treat Cushing&rsquo;s syndrome - when the body produces an excess of cortisol),</p><p>&bull;itraconazole, voriconazole, posaconazole (antifungals),</p><p>&bull;nefazodone (used to treat depression),</p><p>&bull;corticosteroids (such as dexamethasone and methylprednisolone),</p><p>&bull;anti-anxiety medicines (such as alprazolam),</p><p>&bull;tolbutamide (a medicine used to treat diabetes).</p><p>Tell the doctor or pharmacist if you or the child are taking, have recently taken, or might take any other medicines.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>This medicine should not be used during pregnancy unless clearly necessary. If you or the child are pregnant or breast-feeding, may be pregnant or are planning to have a baby, ask the doctor for advice before taking this medicine.</p><p>For information regarding birth control, see &lsquo;Other medicines and <strong>Enevom</strong>&rsquo;.</p><p>It is not known whether <strong>Enevom</strong> is excreted in human milk; therefore, breast-feeding is not recommended during treatment with this medicine. It is important to tell the doctor if you or the child are breast-feeding or are planning to breast-feed before taking this medicine.</p><p><strong>Driving and using machines</strong></p><p>It should be taken into account that some people feel dizzy and sleepy after taking <strong>Enevom</strong>. If you or the child feels dizzy or sleepy, avoid driving, riding a bicycle or using machines or tools after taking this medicine (see &lsquo;Possible side effects&rsquo;).</p><p><strong>Enevom contains sucrose</strong></p><p><strong>Enevom</strong> capsules contain sucrose. If you or the child have been told by your doctor that you or the child have an intolerance to some sugars, contact the doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine or give this medicine to the child exactly as the doctor, pharmacist or nurse has told you. You should check with the doctor, pharmacist or nurse if you are not sure. Always take <strong>Enevom</strong> together with other medicines, to prevent nausea and vomiting. After treatment with <strong>Enevom</strong>, the doctor may ask you or the child to continue taking other medicines including a corticosteroid (such as dexamethasone) and a &lsquo;5HT3 antagonist&rsquo; (such as ondansetron) for preventing nausea and vomiting. Check with the doctor, pharmacist or nurse if you are not sure.</p><p>The recommended oral dose of <strong>Enevom</strong> is</p><p>Day 1:</p><p>&bull;one 125 mg capsule 1 hour before you start your chemotherapy session</p><p><strong>and</strong></p><p>Days 2 and 3:</p><p>&bull;one 80 mg capsule each day</p><p>&bull;If no chemotherapy is given, take <strong>Enevom</strong> in the morning.</p><p>&bull;If chemotherapy is given, take <strong>Enevom</strong> 1 hour before you start your chemotherapy session.</p><p><strong>Enevom</strong><sup>&reg;</sup> can be taken with or without food.</p><p>Swallow the capsule whole with some liquid.</p><p><strong>If you take more Enevom than you should</strong></p><p>Do not take more capsules than the doctor recommends. If you or the child has taken too many capsules, contact your doctor immediately.</p><p><strong>If you forget to take Enevom</strong></p><p>If you or the child has missed a dose, contact your doctor for advice.</p><p>If you have any further questions on the use of this medicine, ask the doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Stop taking Enevom and see a doctor immediately if you or the child notice any of the following side effects, which may be serious, and for which you or the child may need urgent medical treatment:</strong></p><p>&bull;Hives, rash, itching, difficulty breathing or swallowing (frequency not known, cannot be estimated from the available data); these are signs of an allergic reaction.</p><p>Other side effects that have been reported are listed below.</p><p><strong>Common side effects (may affect up to 1 in 10 people) are:</strong></p><p>&bull;constipation, indigestion,</p><p>&bull;headache,</p><p>&bull;tiredness,</p><p>&bull;loss of appetite,</p><p>&bull;hiccups,</p><p>&bull;increased amount of liver enzymes in your blood.</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people) are:</strong></p><p>&bull;dizziness, sleepiness,</p><p>&bull;acne, rash,</p><p>&bull;anxiousness,</p><p>&bull;burping, nausea, vomiting, heartburn, stomach pain, dry mouth, passing wind,</p><p>&bull;increased painful or burning urination,</p><p>&bull;weakness, generally feeling unwell,</p><p>&bull;hot flush/reddening of the face or skin,</p><p>&bull;fast or irregular heartbeats,</p><p>&bull;fever with increased risk of infection, lowering of red blood cells.</p><p><strong>Rare side effects (may affect up to1 in 1,000 people) are:</strong></p><p>&bull;difficulty thinking, lack of energy, taste disturbance,</p><p>&bull;sensitivity of the skin to sun, excessive sweating, oily skin, sores on skin, itching rash, Stevens-Johnson syndrome/toxic epidermal necrolysis (rare severe skin reaction),</p><p>&bull;euphoria (feeling of extreme happiness), disorientation,</p><p>&bull;bacterial infection, fungal infection,</p><p>&bull;severe constipation, stomach ulcer, inflammation of the small intestine and colon, sores in mouth, bloating,</p><p>&bull;frequent urination, passing more urine than normal, presence of sugar or blood in urine,</p><p>&bull;chest discomfort, swelling, change in the manner of walking,</p><p>&bull;cough, mucus in back of throat, throat irritation, sneezing, sore throat,</p><p>&bull;eye discharge and itching,</p><p>&bull;ringing in the ear,</p><p>&bull;muscle spasms, muscle weakness,</p><p>&bull;excessive thirst,</p><p>&bull;slow heartbeat, heart and blood vessel disease,</p><p>&bull;lowering of white blood cells, low sodium levels in the blood, weight loss.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.</p><p>Store in the original package in order to protect from moisture.</p><p>Do not remove the capsule from its blister until you are ready to take it.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;The active substance is aprepitant. Each 125 mg hard capsule contains 125 mg of aprepitant. Each 80 mg hard capsule contains 80 mg of aprepitant.</p><p>&bull;The other ingredients are: sucrose, microcrystalline cellulose (E 460), hydroxypropylcellulose (E 463), sodium laurilsulfate, gelatin, titanium dioxide (E 171), shellac, potassium hydroxide, and black iron oxide (E 172); the 125 mg hard capsule also contains red iron oxide (E 172) and yellow iron oxide (E 172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                The 125 mg hard capsule is opaque with a white body and pink cap with “462” and “125 mg” printed radially in black ink on the body.
The 80 mg hard capsule is opaque with a white cap and body with “461” and “80 mg” printed radially in black ink on the body.
Enevom 125 mg and 80 mg hard capsules are supplied in the following pack size:
•3-day treatment pack containing one 125 mg capsule and two 80 mg capsules
Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MS Pharma Saudi,Riyadh, Kingdome Saudi Arabia.</p><p>info-ksa@mspharma.com</p><p><strong>Manufacturer by:</strong></p><p>Rontis Hellas S.A. - Greece for MS Pharma-Saudi.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                May-2020
SPM190373

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي اينيفوم على المادة الفعالة أبريبيتانت وينتمي إلى مجموعة من الأدوية تسمى &laquo;مضادات مستقبلات نيروكينين 1&raquo;. يمتلك الدماغ منطقة محددة تتحكم في الغثيان والقيء. يعمل</p><p dir="RTL">اينيفوم عن طريق منع الإشارات إلى تلك المنطقة، وبالتالي تقليل الغثيان والقيء. تستخدم كبسولات اينيفوم في البالغين والمراهقين من سن 12 عامًا مع أدوية أخرى لمنع الغثيان والقيء الناجم عن العلاج الكيميائي (علاج السرطان) الذي يتسبب في حدوث غثيان وقئ معتدل (مثل السيسبلاتين، السيكلوفوسفاميد، الدوكسوروبيسين أو إيبيروبوسين).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا<strong> </strong>تأخذ<strong> </strong>اينيفوم<strong> </strong></p><p dir="RTL">- إذا كنت أنت أو الطفل مصابًا بالحساسية تجاه أبريبيتانت أو لأي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6).</p><p dir="RTL">- مع الأدوية التي تحتوي على البيموزيد (تستخدم لعلاج الأمراض النفسية)، تيرفينادين و أستيميزول&nbsp; (المستخدمة في حمى القش وغيرها من الحالات الأرجية)، سيسابريد&nbsp; (تستخدم لعلاج مشاكل في الجهاز الهضمي). أخبر الطبيب إذا كنت أنت أو الطفل يأخذ هذه الأدوية لأن العلاج يجب أن يتم تعديله قبل أن تبدأ أنت أو الطفل في أخذ اينيفوم.</p><p dir="RTL">المحاذير<strong> </strong>والإحتياطات</p><p dir="RTL">تحدث إلى الطبيب أو الصيدلاني أو الممرضة قبل تناول اينيفوم أو إعطاء هذا الدواء للطفل.</p><p dir="RTL">قبل العلاج بهذا الدواء، أخبر الطبيب إذا كنت أنت أو الطفل مصابًا بمرض كبدي لأن الكبد مهم في إخراج الدواء من الجسم. قد يضطر الطبيب إلى مراقبة حالة كبد طفلك أو كبدك.</p><p dir="RTL">الأطفال والمراهقون</p><p dir="RTL">لا تعطي اينيفوم 80ملغم و125ملغم كبسولات للأطفال دون سن 12 سنة من العمر، لأن 80 ملغم و125ملغم كبسولات لم تدرس في هذه الفئة من المرضى.</p><p dir="RTL">أدوية أخرى و اينيفوم.</p><p dir="RTL">يمكن أن يؤثر اينيفوم على الأدوية الأخرى أثناء وبعد العلاج مع اينيفوم. هناك بعض الأدوية التي يجب عدم تناولها مع اينيفوم (مثل البيموزيد والتيرنادين والأستيميزول والسيسبرايد) أو التي تتطلب تعديل الجرعة (انظر أيضًا &laquo;لا تأخذ اينيفوم&raquo;).</p><p dir="RTL">قد يتأثر تأثير اينيفوم مع أدوية أخرى إذا كنت أنت أو الطفل تأخذ اينيفوم مع أدوية أخرى بما في ذلك تلك المذكورة أدناه. يرجى التحدث إلى الطبيب أو الصيدلي إذا كنت أنت أو الطفل يتناول أيًا من الأدوية التالية:</p><p dir="RTL">- أدوية تحديد النسل التي يمكن أن تشمل حبوب منع الحمل، الرقاعة الجلدية، الغرسات، وبعض الأجهزة داخل الرحم (IUDs) التي تطلق الهرمونات والتي قد لا تعمل بشكل كافٍ عند تناولها مع اينيفوم. يجب استخدام شكل آخر غير هرموني من وسائل منع الحمل أثناء العلاج مع اينيفوم ولمدة تصل إلى شهرين بعد استخدام اينيفوم،</p><p dir="RTL">- السيكلوسبورين، تاكروليموس، سيروليموس، ايفيروليموس (أدوية مثبطة للمناعة)،</p><p dir="RTL">- الفنتانيل، الفنتانيل (يستخدم لعلاج الألم)،</p><p dir="RTL">- الكينيدين (يستخدم لعلاج ضربات القلب غير المنتظمة)،</p><p dir="RTL">- إيرينوتيكان، إيتوبوسيد، فينورلبين، إوفو سميد (الأدوية المستخدمة لعلاج السرطان)،</p><p dir="RTL">- الأدوية التي تحتوي على مشتقات قلويد الشقران مثل الإرغوتامين و إرغوتامين&nbsp; الثنائي (تستخدم لعلاج الصداع النصفي)،</p><p dir="RTL">- الوارفارين، اسينوكومارول (مميّزات الدم، اختبارات الدم قد تكون مطلوبة)،</p><p dir="RTL">- ريفامبيسين، كلاريثروميسين، تيليثرومايسين (المضادات الحيوية المستخدمة لعلاج الالتهابات)،</p><p dir="RTL">- الفينيتوين (دواء يستخدم لعلاج النوبات)،</p><p dir="RTL">- كاربامازيبين (يستخدم لعلاج الاكتئاب والصرع)،</p><p dir="RTL">- ميدازولام، تريازولام، فينوباربيتال (الأدوية المهدئة أو مساعدتك على النوم)،</p><p dir="RTL">- نبتة سانت جونز (وهو مستحضر عشبي يستخدم لعلاج الاكتئاب)،</p><p dir="RTL">مثبطات البروتيز (المستخدمة لعلاج عدوى فيروس نقص المناعة البشرية)،</p><p dir="RTL">- الكيتوكونازول ما عدا الشامبو (المستخدم لعلاج متلازمة كوشينغ - عندما ينتج الجسم كمية زائدة من الكورتيزول)،</p><p dir="RTL">- إيتراكونازول، فوريكونازول، بوساكونازول&nbsp; (مضادات الفطريات)،</p><p dir="RTL">- نيفازودون (يستخدم لعلاج الاكتئاب)،</p><p dir="RTL">- الكورتيكوستيرويدات (مثل الديكساميثازون و الميثيل بريدنيزولون)،</p><p dir="RTL">- أدوية مضادة للقلق (مثل ألبرازولام)،</p><p dir="RTL">- تولبوتاميد (دواء يستخدم لعلاج مرض السكري)</p><p dir="RTL">أخبر الطبيب أو الصيدلي إذا كنت أنت أو الطفل يأخذ، أو اتخذت مؤخرا، أو قد تأخذ أي أدوية أخرى.</p><p dir="RTL">الحمل<strong> </strong>والرضاعة<strong> </strong>الطبيعية:</p><p dir="RTL">يجب عدم استخدام هذا الدواء أثناء الحمل ما لم تكن هناك ضرورة واضحة. إذا كنت أنت حاملا أو مرضعة رضاعة طبيعية أو قد تكونين حاملاً أو تخططين لإنجاب طفل، فاستشيري الطبيب قبل تناول هذا الدواء.</p><p dir="RTL">للحصول على معلومات بشأن تحديد النسل، انظر &laquo;أدوية أخرى و اينيفوم&raquo;.</p><p dir="RTL">من غير المعروف ما إذا كان اينيفوم يفرز في حليب الأم. لذلك، لا ينصح بالرضاعة الطبيعية أثناء العلاج بهذا الدواء. من المهم إخبار الطبيب إذا كنت ترضعين رضاعة طبيعية أو تخططين لإرضاع طفلك قبل تناول هذا الدواء.</p><p dir="RTL">القيادة<strong> </strong>واستخدام<strong> </strong>الآلات</p><p dir="RTL">يجب أن يؤخذ في الاعتبار أن بعض الناس يشعرون بالدوار والنعاس بعد أخذ اينيفوم.</p><p dir="RTL">&nbsp;إذا شعرت أنت أو الطفل بالدوار أو النعاس، فتجنب القيادة أو ركوب الدراجة أو استخدام الآلات أو الأدوات بعد تناول هذا الدواء (انظر &laquo;الآثار الجانبية المحتملة&raquo;).</p><p dir="RTL">يحتوي<strong> </strong>اينيفوم<strong> </strong>على<strong> </strong>السكروز</p><p dir="RTL">تحتوي كبسولات اينيفوم على السكروز. إذا أخبرك طبيبك أنت أو الطفل بأن لديك أو الطفل يعاني من عدم تحمل لبعض السكريات، اتصل بالطبيب قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على تناول هذا الدواء أو إعطاء هذا الدواء للطفل تمامًا كما أخبرك الطبيب أو الصيدلي أو الممرضة. يجب عليك مراجعة الطبيب أو الصيدلي أو الممرضة إذا كنت غير متأكد. دائما خذ اينيفوم مع أدوية أخرى، لمنع الغثيان والقيء. بعد العلاج مع اينيفوم، قد يطلب منك الطبيب أو الطفل الاستمرار في تناول أدوية أخرى بما في ذلك كورتيكوستيرويد (مثل ديكساميثازون) ومضادات المستقبلات 5-HT3&nbsp; (مثل أوندانسيترون) لمنع الغثيان والقيء. تحقق مع الطبيب والصيدلي أو الممرضة إذا كنت غير متأكد.</p><p dir="RTL">الجرعة<strong> </strong>عن<strong> </strong>طريق<strong> </strong>الفم<strong> </strong>الموصى<strong> </strong>بها<strong> </strong>من<strong> </strong>اينيفوم<strong> </strong>هو</p><p dir="RTL">اليوم<strong> </strong>1:</p><p dir="RTL">- كبسولة واحدة بتركيز 125 ملغم قبل ساعة من بدء جلسة العلاج الكيميائي</p><p dir="RTL">والأيام<strong> </strong>2<strong> </strong>و<strong> </strong>3:</p><p dir="RTL">- كبسولة واحدة بتركيز 80 ملغم&nbsp; كل يوم</p><p dir="RTL">- إذا لم يتم إعطاء أي علاج كيميائي، فخذ اينيفوم في الصباح.</p><p dir="RTL">- إذا تم إعطاء العلاج الكيميائي، خذ معك اينيفوم قبل ساعة من بدء جلسة العلاج الكيميائي.</p><p dir="RTL">يمكن تناول اينيفوم مع أو بدون الطعام.</p><p dir="RTL">ابتلع الكبسولة كاملة مع بعض السوائل.</p><p dir="RTL">إذا أخذت اينيفوم أكثر مما يجب عليك</p><p dir="RTL">لا تأخذ الكبسولات أكثر مما يوصي به الطبيب. إذا تناولت أنت أو الطفل الكثير من الكبسولات، فاتصل بطبيبك على الفور.</p><p dir="RTL">إذا<strong> </strong>نسيت<strong> </strong>أخذ<strong> </strong>اينيفوم<strong> </strong></p><p dir="RTL">إذا نسيت أنت أو الطفل جرعة ما، استشر طبيبك.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل الطبيب أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، على الرغم من عدم حدوثها في الجميع.</p><p dir="RTL">توقف عن تناول اينيفوم وشاهد الطبيب فورًا إذا لاحظت أنت أو الطفل أيًا من الآثار الجانبية التالية، والتي قد تكون خطيرة، والتي قد تحتاج أنت أو الطفل إلى علاج طبي عاجل:</p><p dir="RTL">- خلايا النحل أو الطفح الجلدي أو الحكة أو صعوبة في التنفس أو البلع (لا يعرف التردد، ولا يمكن تقديره من البيانات المتاحة)؛ هذه هي علامات رد فعل تحسسي.</p><p dir="RTL">الآثار<strong> </strong>الجانبية<strong> </strong>الأخرى<strong> </strong>التي<strong> </strong>تم<strong> </strong>الإبلاغ<strong> </strong>عنها<strong> </strong>ومذكورة<strong> </strong>أدناه.</p><p dir="RTL">الآثار<strong> </strong>الجانبية<strong> </strong>الشائعة<strong> </strong>(قد<strong> </strong>تؤثر<strong> </strong>على<strong> </strong>1<strong> </strong>من<strong> </strong>كل<strong> </strong>10<strong> </strong>أشخاص)<strong> </strong>هي:</p><p dir="RTL">-الإمساك، عسر الهضم،</p><p dir="RTL">-صداع الرأس،</p><p dir="RTL">-التعب،</p><p dir="RTL">-فقدان الشهية،</p><p dir="RTL">-الفواق،</p><p dir="RTL">-زيادة كمية انزيمات الكبد في دمك.</p><p dir="RTL">الآثار<strong> </strong>الجانبية<strong> </strong>غير<strong> </strong>الشائعة<strong> </strong>(قد<strong> </strong>تؤثر<strong> </strong>على<strong> </strong>1<strong> </strong>من<strong> </strong>كل<strong> </strong>100<strong> </strong>شخص)<strong> </strong>هي:</p><p dir="RTL">-الدوخة، النعاس،</p><p dir="RTL">-حب الشباب والطفح الجلدي،</p><p dir="RTL">-الحذر،</p><p dir="RTL">-التجشؤ، والغثيان، والتقيؤ، وحرقة المعدة، وآلام المعدة، وجفاف الفم، والنفخة،</p><p dir="RTL">-زيادة التبول المؤلم أو الحارق،</p><p dir="RTL">-الضعف، والشعور عمومًا بالتوعك،</p><p dir="RTL">-تورد حار / احمرار الوجه أو الجلد</p><p dir="RTL">-ضربات القلب السريعة أو غير المنتظمة،</p><p dir="RTL">-حمى مع زيادة خطر العدوى، وانخفاض خلايا الدم الحمراء.</p><p dir="RTL">الآثار<strong> </strong>الجانبية<strong> </strong>النادرة<strong> </strong>(قد<strong> </strong>تؤثر<strong> </strong>على<strong> </strong>1<strong> </strong>في<strong> </strong>1000<strong> </strong>شخص)<strong> </strong>هي:</p><p dir="RTL">-صعوبة التفكير، نقص الطاقة، اضطراب الذوق،</p><p dir="RTL">-حساسية الجلد للشمس، التعرق الزائد، البشرة الدهنية، التقرحات الجلدية، طفح الحكة، متلازمة ستيفنز جونسون / انحلال البشرة السمي (تفاعل الجلد الحاد النادر)،</p><p dir="RTL">-النشوة (الشعور بالسعادة المفرطة)، التوهان،</p><p dir="RTL">-عدوى بكتيرية، عدوى فطرية،</p><p dir="RTL">-إمساك شديد، قرحة في المعدة، التهاب الأمعاء الدقيقة والقولون، تقرحات في الفم والانتفاخ،</p><p dir="RTL">-التبول المتكرر، تمرير البول أكثر من المعتاد، وجود السكر أو الدم في البول،</p><p dir="RTL">-عدم راحة الصدر، وتورم، وتغيير طريقة المشي،</p><p dir="RTL">-السعال والمخاط في آخر الحنجرة وتهيج الحلق والعطاس والتهاب الحلق،</p><p dir="RTL">-خرجات العين والحكة،</p><p dir="RTL">-رنين في الأذن،</p><p dir="RTL">-التشنجات العضلية وضعف العضلات</p><p dir="RTL">-العطش الشديد،</p><p dir="RTL">-ضربات القلب البطيئة وأمراض القلب والأوعية الدموية</p><p>-انخفاض خلايا الدم البيضاء، وانخفاض مستويات الصوديوم&nbsp;في الدم، وفقدان الوزن.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن متناول ونظر الأطفال.</p><p dir="RTL">&bull; ﻻ ﺗﺴﺘﺨﺪم هذا اﻟﺪواء ﺑﻌﺪ ﺗﺎرﻳﺦ اﻧﺘﻬﺎء اﻟﺼﻼﺣﻴﺔ المذكور ﻋﻠﻰ اﻟﻜﺮﺗﻮنة ﺑﻌﺪ EXP. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">&bull; قم بحفظ الدواء في العبوة الأصلية من أجل الحماية من الرطوبة.</p><p dir="RTL">&bull; ﻻ ﺗﻘﻢ ﺑﺈزاﻟﺔ اﻟﻜﺒﺴﻮﻟﺔ ﻣﻦ الشريط الإ عندما ﺗﻜﻮن ﻣﺴﺘﻌﺪًا لتناولها.</p><p dir="RTL">&bull; لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. هذه التدابير سوف تساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-المادة الفعالة هي أبريبيتانت. كل كبسولة تحتوي على 125 ملغم من أبريبيتانت.</p><p dir="RTL">&nbsp;كل كبسولة تحتوي على 80 ملغم من أبريبيتانت.</p><p dir="RTL">-المكونات الأخرى هي: السكروز، سليلوز دقيق التبلور، هيدروكسيبروبايل سيليلوز، لوريال سلفات الصوديوم، الجيلاتين، ثاني أكسيد التيتانيوم، الشيلاك، وهيدروكسيد البوتاسيوم، وأكسيد الحديد الأسود.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إن الكبسولة الصلبة التي تحتوي على 125 ملغم هي كبسولات بجسم أبيض وغطاء زهري مطبوع عليها &laquo;462&raquo; و &laquo;125 ملغم &laquo; بشكل قطري بالحبر الأسود على الجسم.</p><p dir="RTL">إن الكبسولة الصلبة التي تحتوي على 80 ملغم هي كبسولات بغطاء وجسم أبيض مطبوع عليها &laquo;461&raquo; و &laquo;80 ملغم &laquo; بشكل قطري بالحبر الأسود على الجسم.</p><p dir="RTL">يتم توفير اينيفوم بتركيز 125ملغم و 80ملغم من الكبسولات الصلبة في أحجام العبوات التالية:</p><p dir="RTL">عبوة تحتوي على علاج يكفي لـ3أيام، كبسولة بتركيز 125ملغم و كبسولتين بتركيز 80ملغم.</p><p dir="RTL">ليس جميع احجام العبوات متوفرة في السوق</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إم إس فارما السعودية الرياض ، المملكة العربية السعودية .</p><p dir="RTL">info-ksa@mspharma.com</p><p dir="RTL">صنعت<strong> </strong>بواسطة<strong> </strong>:<strong>&nbsp; </strong></p><p dir="RTL">رونتيس هيلاس إس.أ. اليونان لصالح إم إس فارما &ndash; المملكة العربية السعودية&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مايو - 2020
SPM190373

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Enevom 125 mg hard capsules
Enevom 80 mg hard capsules

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 125 mg capsule contains 125 mg of aprepitant.
 Each 80 mg capsule contains 80 mg of aprepitant.
Excipient with known effect
Each capsule contains 125 mg of sucrose (in the 125 mg capsule).
Excipient with known effect
Each capsule contains 80 mg of sucrose (in the 80 mg capsule).
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard capsule.
The 125 mg capsule is opaque with a white body and pink cap with “462” and “125 mg” printed radially in black ink on the body.
 The 80 mg capsules are opaque with a white body and cap with “461” and “80 mg” printed radially in black ink on the body.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and adolescents from the age of 12.</p><p>ENEVOM 125 mg/80 mg is given as part of combination therapy (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><em><u>Adults</u></em></p><p>ENEVOM is given for 3 days as part of a regimen that includes a corticosteroid and a 5-HT<sub>3</sub>&nbsp;antagonist. The recommended dose is 125 mg orally once daily one hour before start of chemotherapy on Day 1 and 80 mg orally once daily on Days 2 and 3 in the morning.</p><p>The following regimens are recommended in adults for the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy:</p><p><em>Highly Emetogenic Chemotherapy Regimen</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Day 1</p></td><td style="vertical-align:top"><p>Day 2</p></td><td style="vertical-align:top"><p>Day 3</p></td><td style="vertical-align:top"><p>Day 4</p></td></tr><tr><td style="vertical-align:top"><p>ENEVOM</p></td><td style="vertical-align:top"><p>125 mg orally</p></td><td style="vertical-align:top"><p>80 mg orally</p></td><td style="vertical-align:top"><p>80 mg orally</p></td><td style="vertical-align:top"><p>none</p></td></tr><tr><td style="vertical-align:top"><p>Dexamethasone</p></td><td style="vertical-align:top"><p>12 mg orally</p></td><td style="vertical-align:top"><p>8 mg orally</p></td><td style="vertical-align:top"><p>8 mg orally</p></td><td style="vertical-align:top"><p>8 mg orally</p></td></tr><tr><td style="vertical-align:top"><p>5-HT<sub>3</sub>&nbsp;antagonists</p></td><td style="vertical-align:top"><p>Standard dose of 5-HT<sub>3</sub>antagonists. See the product information for the selected 5-HT<sub>3</sub>antagonist for appropriate dosing information</p></td><td style="vertical-align:top"><p>none</p></td><td style="vertical-align:top"><p>none</p></td><td style="vertical-align:top"><p>none</p></td></tr></tbody></table><p><strong>Dexamethasone</strong>&nbsp;should be administered 30 minutes prior to chemotherapy treatment on Day 1 and in the morning on Days 2 to 4. The dose of dexamethasone accounts for active substance interactions.</p><p><em>Moderately Emetogenic Chemotherapy Regimen</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Day 1</p></td><td style="vertical-align:top"><p>Day 2</p></td><td style="vertical-align:top"><p>Day 3</p></td></tr><tr><td style="vertical-align:top"><p>ENEVOM</p></td><td style="vertical-align:top"><p>125 mg orally</p></td><td style="vertical-align:top"><p>80 mg orally</p></td><td style="vertical-align:top"><p>80 mg orally</p></td></tr><tr><td style="vertical-align:top"><p>Dexamethasone</p></td><td style="vertical-align:top"><p>12 mg orally</p></td><td style="vertical-align:top"><p>none</p></td><td style="vertical-align:top"><p>none</p></td></tr><tr><td style="vertical-align:top"><p>5-HT<sub>3</sub>&nbsp;antagonists</p></td><td style="vertical-align:top"><p>Standard dose of 5-HT<sub>3</sub>antagonists. See the product information for the selected 5-HT<sub>3</sub>&nbsp;antagonist for appropriate dosing information</p></td><td style="vertical-align:top"><p>none</p></td><td style="vertical-align:top"><p>none</p></td></tr></tbody></table><p><strong>Dexamethasone&nbsp;</strong>should be administered 30 minutes prior to chemotherapy treatment on Day 1. The dose of dexamethasone accounts for active substance interactions.</p><p><em><u>Paediatric population</u></em></p><p><em>Adolescents (aged 12 through 17 years)</em></p><p>ENEVOM is given for 3 days as part of a regimen that includes a 5-HT<sub>3</sub>&nbsp;antagonist. The recommended dose of capsules of ENEVOM is 125 mg orally on Day 1 and 80 mg orally on Days 2 and 3. ENEVOM is administered orally 1 hour prior to chemotherapy on Days 1, 2 and 3. If no chemotherapy is given on Days 2 and 3, ENEVOM should be administered in the morning. See the Summary of Product Characteristics (SmPC) for the selected 5-HT<sub>3</sub>&nbsp;antagonist for appropriate dosing information. If a corticosteroid, such as dexamethasone, is co-administered with ENEVOM, the dose of the corticosteroid should be administered at 50 % of the usual dose (see sections 4.5 and 5.1).</p><p>The safety and efficacy of the 80 mg and 125 mg capsules have not been demonstrated in children less than 12 years of age. No data are available. Refer to the powder for oral suspension SmPC for appropriate dosing in infants, toddlers and children aged 6 months to less than 12 years.</p><p><em><u>General</u></em></p><p>Efficacy data in combination with other corticosteroids and 5-HT<sub>3</sub>&nbsp;antagonists are limited. For additional information on the co-administration with corticosteroids, see section 4.5. Please refer to the SmPC of co-administered 5-HT<sub>3</sub>antagonist medicinal products.</p><p><em><u>Special populations</u></em></p><p><em>Elderly (&ge; 65 years)</em></p><p>No dose adjustment is necessary for the elderly (see section 5.2).</p><p><em>Gender</em></p><p>No dose adjustment is necessary based on gender (see section 5.2).</p><p><em>Renal impairment</em></p><p>No dose adjustment is necessary for patients with renal impairment or for patients with end stage renal disease undergoing haemodialysis (see section 5.2).</p><p><em>Hepatic impairment</em></p><p>No dose adjustment is necessary for patients with mild hepatic impairment. There are limited data in patients with moderate hepatic impairment and no data in patients with severe hepatic impairment. Aprepitant should be used with caution in these patients (see sections 4.4 and 5.2).</p><p><u>Method of administration</u></p><p>The hard capsule should be swallowed whole.</p><p>ENEVOM may be taken with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Co-administration with pimozide, terfenadine, astemizole or cisapride (see section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Patients with moderate to severe hepatic impairment</u></p><p>There are limited data in patients with moderate hepatic impairment and no data in patients with severe hepatic impairment. ENEVOM should be used with caution in these patients (see section 5.2).</p><p><u>CYP3A4 interactions</u></p><p>ENEVOM should be used with caution in patients receiving concomitant orally administered active substances that are metabolised primarily through CYP3A4 and with a narrow therapeutic range, such as cyclosporine, tacrolimus, sirolimus, everolimus, alfentanil, ergot alkaloid derivatives, fentanyl, and quinidine (see section 4.5). Additionally, concomitant administration with irinotecan should be approached with particular caution as the combination might result in increased toxicity.</p><p><u>Co-administration with warfarin (a CYP2C9 substrate)</u></p><p>In patients on chronic warfarin therapy, the International Normalised Ratio (INR) should be monitored closely during treatment with ENEVOM and for 14 days following each 3-day course of ENEVOM (see section 4.5).</p><p><u>Co-administration with hormonal contraceptives</u></p><p>The efficacy of hormonal contraceptives may be reduced during and for 28 days after administration of ENEVOM. Alternative non-hormonal back-up methods of contraception should be used during treatment with ENEVOM and for 2 months following the last dose of ENEVOM (see section 4.5).</p><p><u>Excipients</u></p><p>ENEVOM capsules contain sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aprepitant (125 mg/80 mg) is a substrate, a moderate inhibitor, and an inducer of CYP3A4. Aprepitant is also an inducer of CYP2C9. During treatment with ENEVOM, CYP3A4 is inhibited. After the end of treatment, ENEVOM causes a transient mild induction of CYP2C9, CYP3A4 and glucuronidation. Aprepitant does not seem to interact with the P-glycoprotein transporter, as suggested by the lack of interaction of aprepitant with digoxin.</p><p><u>Effect aprepitant on the pharmacokinetics of other active substances</u></p><p><em><u>CYP3A4 inhibition</u></em></p><p>As a moderate inhibitor of CYP3A4, aprepitant (125 mg/80 mg) can increase plasma concentrations of co-administered active substances that are metabolised through CYP3A4. The total exposure of orally administered CYP3A4 substrates may increase up to approximately 3-fold during the 3-day treatment with ENEVOM; the effect of aprepitant on the plasma concentrations of intravenously administered CYP3A4 substrates is expected to be smaller. ENEVOM must not be used concurrently with pimozide, terfenadine, astemizole, or cisapride (see section 4.3). Inhibition of CYP3A4 by aprepitant could result in elevated plasma concentrations of these active substances, potentially causing serious or life-threatening reactions. Caution is advised during concomitant administration of ENEVOM and orally administered active substances that are metabolised primarily through CYP3A4 and with a narrow therapeutic range, such as cyclosporine, tacrolimus, sirolimus, everolimus, alfentanil, diergotamine, ergotamine, fentanyl, and quinidine (see section 4.4).</p><p><em>Corticosteroids</em></p><p>Dexamethasone: The usual oral dexamethasone dose should be reduced by approximately 50 % when co-administered with ENEVOM 125 mg/80 mg regimen. The dose of dexamethasone in chemotherapy induced nausea and vomiting clinical trials was chosen to account for active substance interactions (see section 4.2). ENEVOM, when given as a regimen of 125 mg with dexamethasone co-administered orally as 20 mg on Day 1, and ENEVOM when given as 80 mg/day with dexamethasone co-administered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate, 2.2-fold on Days 1 and 5.</p><p>Methylprednisolone: The usual intravenously administered methylprednisolone dose should be reduced approximately 25 %, and the usual oral methylprednisolone dose should be reduced approximately 50 % when co-administered with ENEVOM 125 mg/80 mg regimen. ENEVOM, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1.3-fold on Day 1 and by 2.5-fold on Day 3, when methylprednisolone was co-administered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3.</p><p>During continuous treatment with methylprednisolone, the AUC of methylprednisolone may decrease at later time points within 2 weeks following initiation of the ENEVOM dose, due to the inducing effect of aprepitant on CYP3A4. This effect may be expected to be more pronounced for orally administered methylprednisolone.</p><p><em>Chemotherapeutic medicinal products</em></p><p>In pharmacokinetic studies, ENEVOM, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, did not influence the pharmacokinetics of docetaxel administered intravenously on Day 1 or vinorelbine administered intravenously on Day 1 or Day 8. Because the effect of ENEVOM on the pharmacokinetics of orally administered CYP3A4 substrates is greater than the effect of ENEVOM on the pharmacokinetics of intravenously administered CYP3A4 substrates, an interaction with orally administered chemotherapeutic medicinal products metabolised primarily or partly by CYP3A4 (e.g., etoposide, vinorelbine) cannot be excluded. Caution is advised and additional monitoring may be appropriate in patients receiving medicinal products metabolised primarily or partly by CYP3A4 (see section 4.4). Post-marketing events of neurotoxicity, a potential adverse reaction of ifosfamide, have been reported after aprepitant and ifosfamide co-administration.</p><p><em>Immunosuppressants</em></p><p>During the 3-day CINV regimen, a transient moderate increase followed by a mild decrease in exposure of immunosuppressants metabolised by CYP3A4 (e.g., cyclosporine, tacrolimus, everolimus and sirolimus) is expected. Given the short duration of the 3-day regimen and the time-dependent limited changes in exposure, dose reduction of the immunosuppressant is not recommended during the 3 days of co-administration with ENEVOM.</p><p><em>Midazolam</em></p><p>The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolised via CYP3A4 (alprazolam, triazolam) should be considered when co-administering these medicinal products with ENEVOM (125 mg/80 mg).</p><p>ENEVOM increased the AUC of midazolam, a sensitive CYP3A4 substrate, 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of 2 mg midazolam was co-administered on Days 1 and 5 of a regimen of ENEVOM 125 mg on Day 1 and 80 mg/day on Days 2 to 5.</p><p>In another study with intravenous administration of midazolam, ENEVOM was given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, and 2 mg midazolam was given intravenously prior to the administration of the 3-day regimen of ENEVOM and on Days 4, 8, and 15. ENEVOM increased the AUC of midazolam 25 % on Day 4 and decreased the AUC of midazolam 19 % on Day 8 and 4 % on Day 15. These effects were not considered clinically important.</p><p>In a third study with intravenous and oral administration of midazolam, ENEVOM was given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, together with ondansetron 32 mg Day 1, dexamethasone 12 mg Day 1 and 8 mg Days 2-4. This combination (i.e. ENEVOM, ondansetron and dexamethasone)<strong>&nbsp;</strong>decreased the AUC of oral midazolam 16 % on Day 6, 9 % on Day 8, 7 % on Day 15 and 17 % on Day 22. These effects were not considered clinically important.</p><p>An additional study was completed with intravenous administration of midazolam and ENEVOM. Intravenous 2 mg midazolam was given 1 hour after oral administration of a single dose of ENEVOM 125 mg. The plasma AUC of midazolam was increased by 1.5-fold. This effect was not considered clinically important.</p><p><em><u>Induction</u></em></p><p>As a mild inducer of CYP2C9, CYP3A4 and glucuronidation, aprepitant can decrease plasma concentrations of substrates eliminated by these routes within two weeks following initiation and treatment. This effect may become apparent only after the end of a 3-day treatment with ENEVOM. For CYP2C9 and CYP3A4 substrates, the induction is transient with a maximum effect reached 3-5 days after end of the ENEVOM 3-day treatment. The effect is maintained for a few days, thereafter slowly declines and is clinically insignificant by two weeks after end of ENEVOM treatment. Mild induction of glucuronidation is also seen with 80 mg oral aprepitant given for 7 days. Data are lacking regarding effects on CYP2C8 and CYP2C19. Caution is advised when warfarin, acenocoumarol, tolbutamide, phenytoin or other active substances that are known to be metabolised by CYP2C9 are administered during this time period.</p><p><em>Warfarin</em></p><p>In patients on chronic warfarin therapy, the prothrombin time (INR) should be monitored closely during treatment with ENEVOM and for 2 weeks following each 3-day course of ENEVOM for chemotherapy induced nausea and vomiting (see section 4.4). When a single 125 mg dose of ENEVOM was administered on Day 1 and 80 mg/day on Days 2 and 3 to healthy subjects who were stabilised on chronic warfarin therapy, there was no effect of ENEVOM on the plasma AUC of R(+) or S(-) warfarin determined on Day 3; however, there was a 34 % decrease in S(-) warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14 % decrease in INR 5 days after completion of treatment with ENEVOM.</p><p><em>Tolbutamide</em></p><p>ENEVOM, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23 % on Day 4, 28 % on Day 8, and 15 % on Day 15, when a single dose of tolbutamide 500 mg was administered orally prior to the administration of the 3-day regimen of ENEVOM and on Days 4, 8, and 15.</p><p><em>Hormonal contraceptives</em></p><p>The efficacy of hormonal contraceptives may be reduced during and for 28 days after administration of ENEVOM. Alternative non-hormonal back-up methods of contraception should be used during treatment with ENEVOM and for 2 months following the last dose of ENEVOM.</p><p>In a clinical study, single doses of an oral contraceptive containing ethinyl estradiol and norethindrone were administered on Days 1 through 21 with ENEVOM, given as a regimen of 125 mg on Day 8 and 80 mg/day on Days 9 and 10 with ondansetron 32 mg intravenously on Day 8 and oral dexamethasone given as 12 mg on Day 8 and 8 mg/day on Days 9, 10, and 11. During days 9 through 21 in this study, there was as much as a 64 % decrease in ethinyl estradiol trough concentrations and as much as a 60 % decrease in norethindrone trough concentrations.</p><p><em>5-HT<sub>3</sub>&nbsp;antagonists</em></p><p>In clinical interaction studies, aprepitant did not have clinically important effects on the pharmacokinetics of ondansetron, granisetron, or hydrodolasetron (the active metabolite of dolasetron).</p><p><u>Effect of other medicinal products on the pharmacokinetics of aprepitant</u></p><p>Concomitant administration of ENEVOM with active substances that inhibit CYP3A4 activity (e.g., ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone, and protease inhibitors) should be approached cautiously, as the combination is expected to result several-fold in increased plasma concentrations of aprepitant (see section 4.4).</p><p>Concomitant administration of ENEVOM with active substances that strongly induce CYP3A4 activity (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital) should be avoided as the combination results in reductions of the plasma concentrations of aprepitant that may result in decreased efficacy of ENEVOM. Concomitant administration of ENEVOM with herbal preparations containing St. John&#39;s Wort (<em>Hypericum perforatum)&nbsp;</em>is not recommended.</p><p><em>Ketoconazole</em></p><p>When a single 125 mg dose of aprepitant was administered on Day 5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.</p><p><em>Rifampicin</em></p><p>When a single 375 mg dose of aprepitant was administered on Day 9 of a 14-day regimen of 600 mg/day of rifampicin, a strong CYP3A4 inducer, the AUC of aprepitant decreased 91 % and the mean terminal half-life decreased 68 %.</p><p><em><u>Paediatric population</u></em></p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Contraception in males and females</u></p><p>The efficacy of hormonal contraceptives may be reduced during and for 28 days after administration of ENEVOM. Alternative non-hormonal back-up methods of contraception should be used during treatment with ENEVOM and for 2 months following the last dose of ENEVOM (see sections 4.4 and 4.5).</p><p><u>Pregnancy</u></p><p>For aprepitant no clinical data on exposed pregnancies are available. The potential for reproductive toxicity of aprepitant has not been fully characterised, since exposure levels above the therapeutic exposure in humans at the 125 mg/80 mg dose could not be attained in animal studies. These studies did not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3). The potential effects on reproduction of alterations in neurokinin regulation are unknown. ENEVOM should not be used during pregnancy unless clearly necessary.</p><p><u>Breast-feeding</u></p><p>Aprepitant is excreted in the milk of lactating rats. It is not known whether aprepitant is excreted in human milk; therefore, breast-feeding is not recommended during treatment with ENEVOM.</p><p><u>Fertility</u></p><p>The potential for effects of aprepitant on fertility has not been fully characterised because exposure levels above the therapeutic exposure in humans could not be attained in animal studies. These fertility studies did not indicate direct or indirect harmful effects with respect to mating performance, fertility, embryonic/foetal development, or sperm count and motility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ENEVOM may have minor influence on the ability to drive, cycle and use machines. Dizziness and fatigue may occur following administration of ENEVOM (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The safety profile of aprepitant was evaluated in approximately 6,500 adults in more than 50 studies and 184 children and adolescents in 2 pivotal paediatric clinical trials.</p><p>The most common adverse reactions reported at a greater incidence in adults treated with the aprepitant regimen than with standard therapy in patients receiving Highly Emetogenic Chemotherapy (HEC) were: hiccups (4.6 % versus 2.9 %), alanine aminotransferase (ALT) increased (2.8 % versus 1.1 %), dyspepsia (2.6 % versus 2.0 %), constipation (2.4 % versus 2.0 %), headache (2.0 % versus 1.8 %), and decreased appetite (2.0 % versus 0.5 %). The most common adverse reaction reported at a greater incidence in patients treated with the aprepitant regimen than with standard therapy in patients receiving Moderately Emetogenic Chemotherapy (MEC) was fatigue (1.4 % versus 0.9 %).</p><p>The most common adverse reactions reported at a greater incidence in paediatric patients treated with the aprepitant regimen than with the control regimen while receiving emetogenic cancer chemotherapy were hiccups (3.3 % versus 0.0 %) and flushing (1.1 % versus 0.0 %).</p><p><u>Tabulated list of adverse reactions</u></p><p>The following adverse reactions were observed in a pooled analysis of the HEC and MEC studies at a greater incidence with aprepitant than with standard therapy in adults or paediatric patients or in postmarketing use. The frequency categories given in the table are based on the studies in adults; the observed frequencies in the paediatric studies were similar or lower, unless shown in the table. Some less common ADRs in the adult population were not observed in the paediatric studies.</p><p>Frequencies are defined as: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000) and very rare (&lt; 1/10,000), not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>System organ class</p></td><td style="vertical-align:top"><p>Adverse reaction</p></td><td style="vertical-align:top"><p>Frequency</p></td></tr><tr><td style="vertical-align:top"><p>Infection and infestations</p></td><td style="vertical-align:top"><p>candidiasis, staphylococcal infection</p></td><td style="vertical-align:top"><p>rare</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>febrile neutropenia, anaemia</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>hypersensitivity reactions including anaphylactic reactions</p></td><td style="vertical-align:top"><p>not known</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>decreased appetite</p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>polydipsia</p></td><td style="vertical-align:top"><p>rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>anxiety</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>disorientation, euphoric mood</p></td><td style="vertical-align:top"><p>rare</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>headache</p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>dizziness, somnolence</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>cognitive disorder, lethargy, dysgeusia</p></td><td style="vertical-align:top"><p>rare</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>conjunctivitis</p></td><td style="vertical-align:top"><p>rare</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>tinnitus</p></td><td style="vertical-align:top"><p>rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>palpitations</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>bradycardia, cardiovascular disorder</p></td><td style="vertical-align:top"><p>rare</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>hot flush/flushing</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>hiccups</p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>oropharyngeal pain, sneezing, cough, postnasal drip, throat irritation</p></td><td style="vertical-align:top"><p>rare</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>constipation, dyspepsia</p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>eructation, nausea<sup>&dagger;</sup>, vomiting<sup>&dagger;</sup>, gastroesophageal reflux disease, abdominal pain, dry mouth, flatulence</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>duodenal ulcer perforation, stomatitis, abdominal distension, faeces hard, neutropenic colitis</p></td><td style="vertical-align:top"><p>rare</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>rash, acne</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>photosensitivity reaction, hyperhidrosis, seborrhoea, skin lesion, rash pruritic, Stevens-Johnson syndrome/toxic epidermal necrolysis</p></td><td style="vertical-align:top"><p>rare</p></td></tr><tr><td style="vertical-align:top"><p>pruritus, urticaria</p></td><td style="vertical-align:top"><p>not known</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>muscular weakness, muscle spasms</p></td><td style="vertical-align:top"><p>rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>dysuria</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>pollakiuria</p></td><td style="vertical-align:top"><p>rare</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>fatigue</p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>asthenia, malaise</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>oedema, chest discomfort, gait disturbance</p></td><td style="vertical-align:top"><p>rare</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>ALT increased</p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>AST increased, blood alkaline phosphatase increased</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>red blood cells urine positive, blood sodium decreased, weight decreased, neutrophil count decreased, glucose urine present, urine output increased</p></td><td style="vertical-align:top"><p>rare</p></td></tr></tbody></table><p><sup>&dagger;</sup>Nausea and vomiting were efficacy parameters in the first 5 days of post-chemotherapy treatment and were reported as adverse reactions only thereafter.</p><p><u>Description of selected adverse reactions</u></p><p>The adverse reactions profiles in adults in the Multiple-Cycle extension of HEC and MEC studies for up to 6 additional cycles of chemotherapy were generally similar to those observed in Cycle 1.</p><p>In an additional active-controlled clinical study in 1,169 adult patients receiving aprepitant and HEC, the adverse reactions profile was generally similar to that seen in the other HEC studies with aprepitant.</p><p>Additional adverse reactions were observed in adult patients treated with aprepitant for postoperative nausea and vomiting (PONV) and a greater incidence than with ondansetron: abdominal pain upper, bowel sounds abnormal, constipation*, dysarthria, dyspnoea, hypoaesthesia, insomnia, miosis, nausea, sensory disturbance, stomach discomfort, sub-ileus*, visual acuity reduced, wheezing.</p><p>*Reported in patients taking a higher dose of aprepitant.</p><p><strong>&nbsp;</strong></p><p><strong>To reports any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p dir="RTL"><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:.65pt;margin-top:6.25pt;width:375.05pt;height:100pt;z-index:251659264;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:3.6pt;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:3.6pt;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
 mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal dir=RTL style='mso-layout-grid-align:none;text-autospace:
    none'><span dir=LTR style='font-family:"TimesNewRomanPSMT",serif;
    mso-bidi-font-family:TimesNewRomanPSMT'>- The National Pharmacovigilance
    and Drug Safety Centre (NPC) :<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpFirst style='margin-bottom:10.0pt;mso-add-space:
    auto;text-indent:-18.0pt;line-height:115%;mso-list:l2 level1 lfo1;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>Fax:
    +966-11-205-7662<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='margin-bottom:10.0pt;mso-add-space:
    auto;text-indent:-18.0pt;line-height:115%;mso-list:l2 level1 lfo1;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>Call NPC
    at +966-11-2038222<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='margin-bottom:10.0pt;mso-add-space:
    auto;text-indent:-18.0pt;line-height:115%;mso-list:l2 level1 lfo1;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>Toll free
    phone: 8002490000<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='margin-bottom:10.0pt;mso-add-space:
    auto;text-indent:-18.0pt;line-height:115%;mso-list:l2 level1 lfo1;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>E-mail: </span><a
    href="mailto:npc.drug@sfda.gov.sa"><span style='font-family:"TimesNewRomanPSMT",serif;
    mso-bidi-font-family:TimesNewRomanPSMT'>npc.drug@sfda.gov.sa</span></a><span
    style='font-family:"TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'><o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='margin-bottom:10.0pt;mso-add-space:
    auto;text-indent:-18.0pt;line-height:115%;mso-list:l2 level1 lfo1;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "Times New Roman",serif'>Website: www.sfda.gov.sa</span><span
    style='font-family:"TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'><o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpLast style='margin-bottom:10.0pt;mso-add-space:
    auto;text-indent:-18.0pt;line-height:115%;mso-list:l2 level1 lfo1;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>Website:
    www.sfda.gov.sa/npc<o:p></o:p></span></p>
    <p class=MsoNormal dir=RTL style='text-indent:-18.0pt'><span dir=LTR><o:p>&nbsp;</o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square"/>
</v:shape><![endif]--><img width="506" height="140" alt="Text Box: - The National Pharmacovigilance and Drug Safety Centre (NPC) :
•	Fax: +966-11-205-7662
•	Call NPC at +966-11-2038222
•	Toll free phone: 8002490000
•	E-mail: npc.drug@sfda.gov.sa
•	Website: www.sfda.gov.sa
•	Website: www.sfda.gov.sa/npc

" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States:</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the event of overdose, ENEVOM should be discontinued and general supportive treatment and monitoring should be provided. Because of the antiemetic activity of aprepitant, emesis induced by a medicinal product may not be effective.</p><p>Aprepitant cannot be removed by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antiemetics and antinauseants, ATC code: A04AD12</p><p>Aprepitant is a selective high-affinity antagonist at human substance P neurokinin 1 (NK<sub>1</sub>) receptors.</p><p><u>3-day regimen of aprepitant in adults</u></p><p>In 2 randomised, double-blind studies encompassing a total of 1,094 adult patients receiving chemotherapy that included cisplatin &ge; 70 mg/m<sup>2</sup>, aprepitant in combination with an ondansetron/dexamethasone regimen (see section 4.2) was compared with a standard regimen (placebo plus ondansetron 32 mg intravenously administered on Day 1 plus dexamethasone 20 mg orally on Day 1 and 8 mg orally twice daily on Days 2 to 4). Although a 32 mg intravenous dose of ondansetron was used in clinical trials, this is no longer the recommended dose. See the product information for the selected 5-HT<sub>3</sub>&nbsp;antagonist for appropriate dosing information.</p><p>Efficacy was based on evaluation of the following composite measure: complete response (defined as no emetic episodes and no use of rescue therapy) primarily during Cycle 1. The results were evaluated for each individual study and for the 2 studies combined.</p><p>A summary of the key study results from the combined analysis is shown in Table 1.</p><p>Table 1</p><p>Percent of adult patients receiving Highly Emetogenic Chemotherapy responding by treatment group and phase &mdash; Cycle 1</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td rowspan="2" style="vertical-align:bottom"><p>COMPOSITE MEASURES</p></td><td rowspan="2" style="vertical-align:top"><p>Aprepitant regimen</p><p>(N= 521)<sup>&nbsp;&dagger;</sup></p><p>%</p></td><td rowspan="2" style="vertical-align:top"><p>Standard therapy</p><p>(N= 524)<sup>&nbsp;&dagger;</sup></p><p>%</p></td><td colspan="2" style="vertical-align:top"><p>Differences*</p></td></tr><tr><td style="vertical-align:bottom"><p>%</p></td><td style="vertical-align:bottom"><p>(95 % CI)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Complete response (no emesis and no rescue therapy)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Overall (0-120 hours)</p><p>0-24 hours</p><p>25-120 hours</p></td><td style="vertical-align:top"><p>67.7</p><p>86.0</p><p>71.5</p></td><td style="vertical-align:top"><p>47.8</p><p>73.2</p><p>51.2</p></td><td style="vertical-align:top"><p>19.9</p><p>12.7</p><p>20.3</p></td><td style="vertical-align:top"><p>(14.0, 25.8)</p><p>(7.9, 17.6)</p><p>(14.5, 26.1)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>INDIVIDUAL MEASURES</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>No emesis (no emetic episodes regardless of use of rescue therapy)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Overall (0-120 hours)</p><p>0-24 hours</p><p>25-120 hours</p></td><td style="vertical-align:top"><p>71.9</p><p>86.8</p><p>76.2</p></td><td style="vertical-align:top"><p>49.7</p><p>74.0</p><p>53.5</p></td><td style="vertical-align:top"><p>22.2</p><p>12.7</p><p>22.6</p></td><td style="vertical-align:top"><p>(16.4, 28.0)</p><p>(8.0, 17.5)</p><p>(17.0, 28.2)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>No significant nausea (maximum VAS &lt; 25 mm on a scale of 0-100 mm)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Overall (0-120 hours)</p><p>25-120 hours</p></td><td style="vertical-align:top"><p>72.1</p><p>74.0</p></td><td style="vertical-align:top"><p>64.9</p><p>66.9</p></td><td style="vertical-align:top"><p>7.2</p><p>7.1</p></td><td style="vertical-align:top"><p>(1.6, 12.8)</p><p>(1.5, 12.6)</p></td></tr></tbody></table><p>* The confidence intervals were calculated with no adjustment for gender and concomitant chemotherapy, which were included in the primary analysis of odds ratios and logistic models.</p><p><sup>&dagger;&nbsp;</sup>One patient in the Aprepitant regimen only had data in the acute phase and was excluded from the overall and delayed phase analyses; one patient in the Standard regimen only had data in the delayed phase and was excluded from the overall and acute phase analyses.</p><p>The estimated time to first emesis in the combined analysis is depicted by the Kaplan-Meier plot in Figure 1.</p><p>Figure 1</p><p>Percent of adult patients receiving Highly Emetogenic Chemotherapy who remain emesis free over time &ndash; Cycle 1</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_5" o:spid="_x0000_i1026" type="#_x0000_t75"
 alt="https://www.medicines.org.uk/emc/images/spc/spc~13868~20~145781A.PNG"
 style='width:319.5pt;height:213.75pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title="spc~13868~20~145781A"/>
</v:shape><![endif]--><img width="426" height="285" alt="https://www.medicines.org.uk/emc/images/spc/spc~13868~20~145781A.PNG" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></p><p>Statistically significant differences in efficacy were also observed in each of the 2 individual studies.</p><p>In the same 2 clinical studies, 851 adult patients continued into the Multiple-Cycle extension for up to 5 additional cycles of chemotherapy. The efficacy of the aprepitant regimen was apparently maintained during all cycles.</p><p>In a randomised, double-blind study in a total of 866 adult patients (864 females, 2 males) receiving chemotherapy that included cyclophosphamide 750-1,500 mg/m<sup>2</sup>; or cyclophosphamide 500-1,500 mg/m<sup>2</sup>&nbsp;and doxorubicin (&le; 60 mg/m<sup>2</sup>) or epirubicin (&le; 100 mg/m<sup>2</sup>), aprepitant in combination with an ondansetron/dexamethasone regimen (see section 4.2) was compared with standard therapy (placebo plus ondansetron 8 mg orally (twice on Day 1, and every 12 hours on Days 2 and 3) plus dexamethasone 20 mg orally on Day 1).</p><p>Efficacy was based on evaluation of the composite measure: complete response (defined as no emetic episodes and no use of rescue therapy) primarily during Cycle 1.</p><p>A summary of the key study results is shown in Table 2.</p><p>Table 2</p><p>Percent of adult patients responding by treatment group and phase &mdash; Cycle 1</p><p>Moderately Emetogenic Chemotherapy</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td rowspan="2" style="vertical-align:bottom"><p>COMPOSITE MEASURES</p></td><td rowspan="2" style="vertical-align:top"><p>Aprepitant regimen</p><p>(N= 433)<sup>&nbsp;&dagger;</sup></p><p>%</p></td><td rowspan="2" style="vertical-align:top"><p>Standard therapy</p><p>(N= 424)</p><p>%</p></td><td colspan="2" style="vertical-align:top"><p>Differences*</p></td></tr><tr><td style="vertical-align:bottom"><p>%</p></td><td style="vertical-align:bottom"><p>(95 % CI)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Complete response (no emesis and no rescue therapy)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Overall (0-120 hours)</p><p>0-24 hours</p><p>25-120 hours</p></td><td style="vertical-align:top"><p>50.8</p><p>75.7</p><p>55.4</p></td><td style="vertical-align:top"><p>42.5</p><p>69.0</p><p>49.1</p></td><td style="vertical-align:top"><p>8.3</p><p>6.7</p><p>6.3</p></td><td style="vertical-align:top"><p>(1.6, 15.0)</p><p>(0.7, 12.7)</p><p>(-0.4, 13.0)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>INDIVIDUAL MEASURES</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>No emesis (no emetic episodes regardless of use of rescue therapy)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Overall (0-120 hours)</p><p>0-24 hours</p><p>25-120 hours</p></td><td style="vertical-align:top"><p>75.7</p><p>87.5</p><p>80.8</p></td><td style="vertical-align:top"><p>58.7</p><p>77.3</p><p>69.1</p></td><td style="vertical-align:top"><p>17.0</p><p>10.2</p><p>11.7</p></td><td style="vertical-align:top"><p>(10.8, 23.2)</p><p>(5.1, 15.3)</p><p>(5.9, 17.5)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>No significant nausea (maximum VAS &lt; 25 mm on a scale of 0-100 mm)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Overall (0-120 hours)</p><p>0-24 hours</p><p>25-120 hours</p></td><td style="vertical-align:top"><p>60.9</p><p>79.5</p><p>65.3</p></td><td style="vertical-align:top"><p>55.7</p><p>78.3</p><p>61.5</p></td><td style="vertical-align:top"><p>5.3</p><p>1.3</p><p>3.9</p></td><td style="vertical-align:top"><p>(-1.3, 11.9)</p><p>(-4.2, 6.8)</p><p>(-2.6, 10.3)</p></td></tr></tbody></table><p>* The confidence intervals were calculated with no adjustment for age category (&lt; 55 years, &ge; 55 years) and investigator group, which were included in the primary analysis of odds ratios and logistic models.</p><p><sup>&dagger;</sup>&nbsp;One patient in the Aprepitant regimen only had data in the acute phase and was excluded from the overall and delayed phase analyses.</p><p>In the same clinical study, 744 adult patients continued into the Multiple-Cycle extension for up to 3 additional cycles of chemotherapy. The efficacy of the aprepitant regimen was apparently maintained during all cycles.</p><p>In a second multicentre, randomised, double-blind, parallel-group, clinical study, the aprepitant regimen was compared with standard therapy in 848 adult patients (652 females, 196 males) receiving a chemotherapy regimen that included any intravenous dose of oxaliplatin, carboplatin, epirubicin, idarubicin, ifosfamide, irinotecan, daunorubicin, doxorubicin; cyclophosphamide intravenously (&lt; 1,500 mg/m<sup>2</sup>); or cytarabine intravenously (&gt; 1 g/m<sup>2</sup>). Patients receiving the aprepitant regimen were receiving chemotherapy for a variety of tumour types including 52 % with breast cancer, 21 % with gastrointestinal cancers including colorectal cancer, 13 % with lung cancer and 6 % with gynaecological cancers. The aprepitant regimen in combination with an ondansetron/dexamethasone regimen (see section 4.2) was compared with standard therapy (placebo in combination with ondansetron 8 mg orally (twice on Day 1, and every 12 hours on Days 2 and 3) plus dexamethasone 20 mg orally on Day 1).</p><p>Efficacy was based on the evaluation of the following primary and key secondary endpoints: No vomiting in the overall period (0 to 120 hours post-chemotherapy), evaluation of safety and tolerability of the aprepitant regimen for chemotherapy induced nausea and vomiting (CINV), and complete response (defined as no vomiting and no use of rescue therapy) in the overall period (0 to 120 hours post-chemotherapy). Additionally, no significant nausea in the overall period (0 to 120 hours post-chemotherapy) was evaluated as an exploratory endpoint, and in the acute and delayed phases as a post-hoc analysis.</p><p>A summary of the key study results is shown in Table 3.</p><p>Table 3</p><p>Percent of adult patients responding by treatment group and phase for Study 2 &ndash; Cycle 1</p><p>Moderately Emetogenic Chemotherapy</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td rowspan="2" style="vertical-align:top">&nbsp;</td><td rowspan="2" style="vertical-align:top"><p>Aprepitant regimen</p><p>(N= 425)</p><p>%</p></td><td rowspan="2" style="vertical-align:top"><p>Standard therapy</p><p>(N= 406)</p><p>%</p></td><td colspan="2" style="vertical-align:top"><p>Differences*</p></td></tr><tr><td style="vertical-align:bottom"><p>%</p></td><td style="vertical-align:bottom"><p>(95 % CI)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Complete response (no emesis and no rescue therapy)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Overall (0-120 hours)</p><p>0-24 hours</p><p>25-120 hours</p></td><td style="vertical-align:top"><p>68.7</p><p>89.2</p><p>70.8</p></td><td style="vertical-align:top"><p>56.3</p><p>80.3</p><p>60.9</p></td><td style="vertical-align:top"><p>12.4</p><p>8.9</p><p>9.9</p></td><td style="vertical-align:top"><p>(5.9, 18.9)</p><p>(4.0, 13.8)</p><p>(3.5, 16.3)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>No emesis (no emetic episodes regardless of use of rescue therapy)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Overall (0-120 hours)</p><p>0-24 hours</p><p>25-120 hours</p></td><td style="vertical-align:top"><p>76.2</p><p>92.0</p><p>77.9</p></td><td style="vertical-align:top"><p>62.1</p><p>83.7</p><p>66.8</p></td><td style="vertical-align:top"><p>14.1</p><p>8.3</p><p>11.1</p></td><td style="vertical-align:top"><p>(7.9, 20.3)</p><p>(3.9, 12.7)</p><p>(5.1, 17.1)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>No significant nausea (maximum VAS &lt; 25 mm on a scale of 0-100 mm)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Overall (0-120 hours)</p><p>0-24 hours</p><p>25-120 hours</p></td><td style="vertical-align:top"><p>73.6</p><p>90.9</p><p>74.9</p></td><td style="vertical-align:top"><p>66.4</p><p>86.3</p><p>69.5</p></td><td style="vertical-align:top"><p>7.2</p><p>4.6</p><p>5.4</p></td><td style="vertical-align:top"><p>(1.0, 13.4)</p><p>(0.2, 9.0)</p><p>(-0.7, 11.5)</p></td></tr></tbody></table><p>*The confidence intervals were calculated with no adjustment for gender and region, which were included in the primary analysis using logistic models.</p><p>The benefit of aprepitant combination therapy in the full study population was mainly driven by the results observed in patients with poor control with the standard regimen such as in women, even though the results were numerically better regardless of age, tumour type or gender. Complete response to the aprepitant regimen and standard therapy, respectively, was reached in 209/324 (65 %) and 161/320 (50 %) in women and 83/101 (82 %) and 68/87 (78 %) of men.</p><p><u>Paediatric population</u></p><p>In a randomised, double-blind, active comparator-controlled clinical study that included 302 children and adolescents (aged 6 months to 17 years) receiving moderately or highly emetogenic chemotherapy, the aprepitant regimen was compared to a control regimen for the prevention of CINV. The efficacy of the aprepitant regimen was evaluated in a single cycle (Cycle 1). Patients had the opportunity to receive open-label aprepitant in subsequent cycles (Optional Cycles 2-6); however efficacy was not assessed in these optional cycles. The aprepitant regimen for adolescents aged 12 through 17 years (n=47) consisted of ENEVOM capsules 125 mg orally on Day 1 and 80 mg/day on Days 2 and 3 in combination with ondansetron on Day 1. The aprepitant regimen for children aged 6 months to less than 12 years (n=105) consisted of ENEVOM powder for oral suspension 3.0 mg/kg (up to 125 mg) orally on Day 1 and 2.0 mg/kg (up to 80 mg) orally on Days 2 and 3 in combination with ondansetron on Day 1. The control regimen in adolescents aged 12 through 17 years (n=48) and children aged 6 months to less than 12 years (n=102) consisted of placebo for aprepitant on Days 1, 2 and 3 in combination with ondansetron on Day 1. ENEVOM or placebo and ondansetron were administered 1 hour and 30 minutes prior to initiation of chemotherapy, respectively. Intravenous dexamethasone was permitted as part of the antiemetic regimen for paediatric patients in both age groups, at the discretion of the physician. A dose reduction (50 %) of dexamethasone was required for paediatric patients receiving aprepitant. No dose reduction was required for paediatric patients receiving the control regimen. Of the paediatric patients, 29 % in the aprepitant regimen and 28 % in the control regimen used dexamethasone as part of the regimen in Cycle 1.</p><p>The antiemetic activity of ENEVOM was evaluated over a 5-day (120 hour) period following the initiation of chemotherapy on Day 1. The primary endpoint was complete response in the delayed phase (25 to 120 hours following initiation of chemotherapy) in Cycle 1. A summary of the key study results are shown in Table 4.</p><p>Table 4</p><p>Number (%) of paediatric patients with complete response and no vomiting by treatment group and phase &ndash; Cycle 1 (Intent to treat population)</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Aprepitant regimen</p><p>n/m (%)</p></td><td style="vertical-align:top"><p>Control regimen</p><p>n/m (%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>PRIMARY ENDPOINT</p></td></tr><tr><td style="vertical-align:top"><p>Complete response* &ndash; Delayed phase</p></td><td style="vertical-align:top"><p>77/152 (50.7)<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>39/150 (26.0)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>OTHER PRESPECIFIED ENDPOINTS</p></td></tr><tr><td style="vertical-align:top"><p>Complete response* &ndash; Acute phase</p></td><td style="vertical-align:top"><p>101/152 (66.4)<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>78/150 (52.0)</p></td></tr><tr><td style="vertical-align:top"><p>Complete response* &ndash; Overall phase</p></td><td style="vertical-align:top"><p>61/152 (40.1)<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>30/150 (20.0)</p></td></tr><tr><td style="vertical-align:top"><p>No vomiting<sup>&sect;</sup>&nbsp;&ndash; Overall phase</p></td><td style="vertical-align:top"><p>71/152 (46.7)<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>32/150 (21.3)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*Complete response = No vomiting or retching or dry heaves and no use of rescue medication.</p><p><sup>&dagger;</sup>p &lt; 0.01 when compared to control regimen</p><p><sup>&Dagger;</sup>p &lt; 0.05 when compared to control regimen</p><p><sup>&sect;</sup>No vomiting = No vomiting or retching or dry heaves</p><p>n/m = Number of patients with desired response/number of patients included in time point.</p><p>Acute phase: 0 to 24 hours following initiation of chemotherapy.</p><p>Delayed phase: 25 to 120 hours following initiation of chemotherapy.</p><p>Overall phase: 0 to 120 hours following initiation of chemotherapy.</p></td></tr></tbody></table><p>The estimated time to first vomiting after initiation of chemotherapy treatment was longer with the aprepitant regimen (estimated median time to first vomiting was 94.5 hours) compared with the control regimen group (estimated median time to first vomiting was 26.0 hours) as depicted in the Kaplan-Meier curves in Figure 2.</p><p>Figure 2</p><p>Time to first vomiting episode from start of chemotherapy administration - paediatric patients in the overall phase-Cycle 1 (Intent to treat population)</p><p><!--[if gte vml 1]><v:shape
 id="Picture_x0020_4" o:spid="_x0000_i1025" type="#_x0000_t75" alt="https://www.medicines.org.uk/emc/images/spc/spc~13868~20~image2.png"
 style='width:318pt;height:192.75pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
  o:title="spc~13868~20~image2"/>
</v:shape><![endif]--><img width="424" height="257" alt="https://www.medicines.org.uk/emc/images/spc/spc~13868~20~image2.png" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /></p><p>An analysis of efficacy in subpopulations in Cycle 1 demonstrated that, regardless of age category, gender, use of dexamethasone for antiemetic prophylaxis, and emetogenicity of chemotherapy, the aprepitant regimen provided better control than the control regimen with respect to the complete response endpoints.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aprepitant displays non-linear pharmacokinetics. Both clearance and absolute bioavailability decrease with increasing dose.</p><p><u>Absorption</u></p><p>The mean absolute oral bioavailability of aprepitant is 67 % for the 80 mg capsule and 59 % for the 125 mg capsule. The mean peak plasma concentration (C<sub>max</sub>) of aprepitant occurred at approximately 4 hours (t<sub>max</sub>). Oral administration of the capsule with an approximately 800 Kcal standard breakfast resulted in an up to 40 % increase in AUC of aprepitant. This increase is not considered clinically relevant.</p><p>The pharmacokinetics of aprepitant is non-linear across the clinical dose range. In healthy young adults, the increase in AUC<sub>0-&infin;&nbsp;</sub>was 26 % greater than dose proportional between 80 mg and 125 mg single doses administered in the fed state.</p><p>Following oral administration of a single 125 mg dose of ENEVOM on Day 1 and 80 mg once daily on Days 2 and 3, the AUC<sub>0-24hr&nbsp;</sub>(mean&plusmn;SD) was 19.6 &plusmn; 2.5 &micro;g&bull;h/mL and 21.2 &plusmn; 6.3 &micro;g &bull;h/mL on Days 1 and 3, respectively. C<sub>max</sub>&nbsp;was 1.6 &plusmn; 0.36 &micro;g/mL and 1.4 &plusmn; 0.22 &micro;g/mL on Days 1 and 3, respectively.</p><p><u>Distribution</u></p><p>Aprepitant is highly protein bound, with a mean of 97 %. The geometric mean apparent volume of distribution at steady state (Vd<sub>ss</sub>) is approximately 66 L in humans.</p><p><u>Biotransformation</u></p><p>Aprepitant undergoes extensive metabolism. In healthy young adults, aprepitant accounts for approximately 19 % of the radioactivity in plasma over 72 hours following a single intravenous administration 100-mg dose of [<sup>14</sup>C]-fosaprepitant, a prodrug for aprepitant, indicating a substantial presence of metabolites in the plasma. Twelve metabolites of aprepitant have been identified in human plasma. The metabolism of aprepitant occurs largely via oxidation at the morpholine ring and its side chains and the resultant metabolites were only weakly active.&nbsp;<em>In vitro&nbsp;</em>studies using human liver microsomes indicate that aprepitant is metabolised primarily by CYP3A4 and potentially with minor contribution by CYP1A2 and CYP2C19.</p><p><u>Elimination</u></p><p>Aprepitant is not excreted unchanged in urine. Metabolites are excreted in urine and via biliary excretion in faeces. Following a single intravenously administered 100 mg dose of [<sup>14</sup>C]-fosaprepitant, a prodrug for aprepitant, to healthy subjects, 57 % of the radioactivity was recovered in urine and 45 % in faeces.</p><p>The plasma clearance of aprepitant is dose-dependent, decreasing with increased dose and ranged from approximately 60 to 72 mL/min in the therapeutic dose range. The terminal half-life ranged from approximately 9 to 13 hours.</p><p><u>Pharmacokinetics in special populations</u></p><p><em>Elderly</em>: Following oral administration of a single 125 mg dose of aprepitant on Day 1 and 80 mg once daily on Days 2 through 5, the AUC<sub>0-24hr</sub>&nbsp;of aprepitant was 21 % higher on Day 1 and 36 % higher on Day 5 in elderly (&ge; 65 years) relative to younger adults. The C<sub>max</sub>&nbsp;was 10 % higher on Day 1 and 24 % higher on Day 5 in elderly relative to younger adults. These differences are not considered clinically meaningful. No dose adjustment for ENEVOM is necessary in elderly patients.</p><p><em>Gender</em>: Following oral administration of a single 125 mg dose of aprepitant, the C<sub>max&nbsp;</sub>for aprepitant is 16 % higher in females as compared with males. The half-life of aprepitant is 25 % lower in females as compared with males and its t<sub>max</sub>&nbsp;occurs at approximately the same time. These differences are not considered clinically meaningful. No dose adjustment for ENEVOM is necessary based on gender.</p><p><em>Hepatic impairment</em>: Mild hepatic impairment (Child-Pugh class A) does not affect the pharmacokinetics of aprepitant to a clinically relevant extent. No dose adjustment is necessary for patients with mild hepatic impairment. Conclusions regarding the influence of moderate hepatic impairment (Child-Pugh class B) on aprepitant pharmacokinetics cannot be drawn from available data. There are no clinical or pharmacokinetic data in patients with severe hepatic impairment (Child-Pugh class C).</p><p><em>Renal impairment</em>: A single 240 mg dose of aprepitant was administered to patients with severe renal impairment (CrCl &lt; 30 mL/min) and to patients with end stage renal disease (ESRD) requiring haemodialysis.</p><p>In patients with severe renal impairment, the AUC<sub>0-&infin;&nbsp;</sub>of total aprepitant (unbound and protein bound) decreased by 21 % and C<sub>max</sub>&nbsp;decreased by 32 %, relative to healthy subjects. In patients with ESRD undergoing haemodialysis, the AUC<sub>0-&infin;</sub>of total aprepitant decreased by 42 % and C<sub>max</sub>&nbsp;decreased by 32 %. Due to modest decreases in protein binding of aprepitant in patients with renal disease, the AUC of pharmacologically active unbound aprepitant was not significantly affected in patients with renal impairment compared with healthy subjects. Haemodialysis conducted 4 or 48 hours after dosing had no significant effect on the pharmacokinetics of aprepitant; less than 0.2 % of the dose was recovered in the dialysate.</p><p>No dose adjustment for ENEVOM is necessary for patients with renal impairment or for patients with ESRD undergoing haemodialysis.</p><p><em>Paediatric population</em>: As part of a 3-day regimen, dosing of aprepitant capsules (125/80/80-mg) in adolescent patients (aged 12 through 17 years) achieved an AUC<sub>0-24hr</sub>&nbsp;above 17 &micro;g&bull;hr/mL on Day 1 with concentrations (C<sub>min</sub>) at the end of Days 2 and 3 above 0.4 &micro;g/mL in a majority of patients. The median peak plasma concentration (C<sub>max</sub>) was approximately 1.3 &micro;g/mL on Day 1, occurring at approximately 4 hours. As part of a 3-day regimen, dosing of aprepitant powder for oral suspension (3/2/2-mg/kg) in patients aged 6 months to less than12 years achieved an AUC<sub>0-24hr</sub>&nbsp;above 17 &micro;g&bull;hr/mL on Day 1 with concentrations (C<sub>min</sub>) at the end of Days 2 and 3 above 0.1 &micro;g/mL in a majority of patients. The median peak plasma concentration (C<sub>max</sub>) was approximately 1.2 &micro;g/mL on Day 1, occurring between 5 and 7 hours.</p><p>A population pharmacokinetic analysis of aprepitant in paediatric patients (aged 6 months through 17 years) suggests that gender and race have no clinically meaningful effect on the pharmacokinetics of aprepitant.</p><p><u>Relationship between concentration and effect</u></p><p>Using a highly specific NK<sub>1</sub>-receptor tracer, positron emission tomography (PET) studies in healthy young men have shown that aprepitant penetrates into the brain and occupies NK<sub>1</sub>&nbsp;receptors in a dose- and plasma-concentration-dependent manner. Aprepitant plasma concentrations achieved with the 3-day regimen of ENEVOM in adults are predicted to provide greater than 95 % occupancy of brain NK<sub>1</sub>&nbsp;receptors.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pre-clinical data reveal no special hazard for humans based on conventional studies of single and repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development. However, it should be noted that systemic exposure in rodents was similar or even lower than therapeutic exposure in humans at the 125 mg/80 mg dose. In particular, although no adverse effects were noted in reproduction studies at human exposure levels, the animal exposures are not sufficient to make an adequate risk assessment in man.</p><p>In a juvenile toxicity study in rats treated from post natal day 10 to day 63 aprepitant led to an earlier vaginal opening in females from 250 mg/kg b.i.d. and to a delayed preputial separation in males, from 10 mg/kg b.i.d. There were no margins to clinically relevant exposure. There were no treatment-related effects on mating, fertility or embryonic/foetal survival, and no pathological changes in the reproductive organs. In a juvenile toxicity study in dogs treated from post natal day 14 to day 42, a decreased testicular weight and Leydig cell size were seen in the males at 6 mg/kg/day and increased uterine weight, hypertrophy of the uterus and cervix, and oedema of vaginal tissues were seen in females from 4 mg/kg/day. There were no margins to clinically relevant exposure of aprepitant. For short term treatment according to recommended dose regimen these findings are considered unlikely to be clinically relevant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Capsule content</u></p><p>Sucrose</p><p>Microcrystalline cellulose (E 460)</p><p>Hydroxypropylcellulose (E 463)</p><p>Sodium laurilsulfate</p><p><u>Capsule shell (125 mg)</u></p><p>Gelatin</p><p>Titanium dioxide (E 171)</p><p>Red iron oxide (E 172)</p><p><u>Capsule shell (80 mg)</u></p><p>Gelatin</p><p>Titanium dioxide (E 171)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30C</p><p>Store in the original package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Different pack sizes including different strengths are available.</p><p>Aluminium blister containing one 80 mg capsule.</p><p>Aluminium blister containing two 80 mg capsules.</p><p>5 Aluminium blisters each containing one 80 mg capsule.</p><p>Aluminium blister containing one 125 mg capsule.</p><p>5 Aluminium blisters each containing one 125 mg capsule.</p><p>Aluminium blister containing one 125 mg capsule and two 80 mg capsules</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MS Pharma Saudi,
Grand center 1st floor,
Alrabiea area - King Abdulaziz Road,
Riyadh, Kingdome Saudi Arabia
P.O.Box 54850
Phone: +966112790122
RegulatoryKSA@mspharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Apr-19
SPC-013-0419-00

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>